Literature DB >> 28236061

The Routine Clinical use of Pharmacogenetic Tests: What it Will Require?

Mafalda M Dias1,2, Michael J Sorich2,3, Andrew Rowland2,3, Michael D Wiese1, Ross A McKinnon4.   

Abstract

Pharmacogenetic testing aims to personalize drug therapy with a view to optimising drug efficacy and minimise toxicity. However, despite the potential benefits, pharmacogenetic testing is mostly confined to specialised medical areas, laboratories and centres. Widespread integration into routine clinical practice has been limited by a complex set of issues including regulatory and reimbursement frameworks, evidence of clinical utility and clinician perspectives, practices and education. Here we assess the current barriers to widespread clinical uptake and identify the key issue necessary to address to accelerate routine testing.

Entities:  

Keywords:  biomarkers; clinical uptake; diagnostic tests; personalized medicine

Mesh:

Substances:

Year:  2017        PMID: 28236061     DOI: 10.1007/s11095-017-2128-0

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  85 in total

Review 1.  Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review.

Authors:  K A Phillips; D L Veenstra; E Oren; J K Lee; W Sadee
Journal:  JAMA       Date:  2001-11-14       Impact factor: 56.272

Review 2.  Clinical significance of prognostic and predictive markers in colorectal cancer.

Authors:  D B Longley; U McDermott; P G Johnston
Journal:  Pharmacogenomics J       Date:  2002       Impact factor: 3.550

3.  Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease.

Authors:  Kirk E Lohmueller; Celeste L Pearce; Malcolm Pike; Eric S Lander; Joel N Hirschhorn
Journal:  Nat Genet       Date:  2003-01-13       Impact factor: 38.330

Review 4.  Barriers to the provision of genetic services by primary care physicians: a systematic review of the literature.

Authors:  Sandy Suther; Patricia Goodson
Journal:  Genet Med       Date:  2003 Mar-Apr       Impact factor: 8.822

5.  The human genome project is complete. How do we develop a handle for the pump?

Authors:  Julian Little; Muin J Khoury; Linda Bradley; Mindy Clyne; Marta Gwinn; Bruce Lin; Mary-Lou Lindegren; Paula Yoon
Journal:  Am J Epidemiol       Date:  2003-04-15       Impact factor: 4.897

Review 6.  From pharmacogenetics to personalized medicine: a vital need for educating health professionals and the community.

Authors:  Felix W Frueh; David Gurwitz
Journal:  Pharmacogenomics       Date:  2004-07       Impact factor: 2.533

Review 7.  Criteria influencing the clinical uptake of pharmacogenomic strategies.

Authors:  Jai Shah
Journal:  BMJ       Date:  2004-06-19

Review 8.  Integrating pharmacogenetics into society: in search of a model.

Authors:  Andrew Webster; Paul Martin; Graham Lewis; Andrew Smart
Journal:  Nat Rev Genet       Date:  2004-09       Impact factor: 53.242

Review 9.  A network of investigator networks in human genome epidemiology.

Authors:  John P A Ioannidis; Jonine Bernstein; Paolo Boffetta; John Danesh; Siobhan Dolan; Patricia Hartge; David Hunter; Peter Inskip; Marjo-Riitta Jarvelin; Julian Little; Demetrius M Maraganore; Julia A Newton Bishop; Thomas R O'Brien; Gloria Petersen; Elio Riboli; Daniela Seminara; Emanuela Taioli; André G Uitterlinden; Paolo Vineis; Deborah M Winn; Georgia Salanti; Julian P T Higgins; Muin J Khoury
Journal:  Am J Epidemiol       Date:  2005-07-13       Impact factor: 4.897

10.  Drug-related morbidity and mortality: updating the cost-of-illness model.

Authors:  F R Ernst; A J Grizzle
Journal:  J Am Pharm Assoc (Wash)       Date:  2001 Mar-Apr
View more
  5 in total

Review 1.  The Role of Next-Generation Sequencing in Pharmacogenetics and Pharmacogenomics.

Authors:  Ute I Schwarz; Markus Gulilat; Richard B Kim
Journal:  Cold Spring Harb Perspect Med       Date:  2019-02-01       Impact factor: 6.915

2.  Plasma extracellular nanovesicle (exosome)-derived biomarkers for drug metabolism pathways: a novel approach to characterize variability in drug exposure.

Authors:  Andrew Rowland; Warit Ruanglertboon; Madelé van Dyk; Dhilushi Wijayakumara; Linda S Wood; Robyn Meech; Peter I Mackenzie; A David Rodrigues; Jean-Claude Marshall; Michael J Sorich
Journal:  Br J Clin Pharmacol       Date:  2018-11-16       Impact factor: 4.335

Review 3.  Nuances to precision dosing strategies of targeted cancer medicines.

Authors:  Ashley M Hopkins; Bradley D Menz; Michael D Wiese; Ganessan Kichenadasse; Howard Gurney; Ross A McKinnon; Andrew Rowland; Michael J Sorich
Journal:  Pharmacol Res Perspect       Date:  2020-08

4.  Pharmacogenomics Implementation and Hurdles to Overcome; In the Context of a Developing Country.

Authors:  Nayyereh Ayati; Monireh Afzali; Mandana Hasanzad; Abbas Kebriaeezadeh; Ali Rajabzadeh; Shekoufeh Nikfar
Journal:  Iran J Pharm Res       Date:  2021       Impact factor: 1.696

Review 5.  Effect of Pharmacogenetic-Based Decision Support Tools in Improving Depression Outcomes: A Systematic Review.

Authors:  Shimaa Aboelbaha; Monica Zolezzi; Hazem Elewa
Journal:  Neuropsychiatr Dis Treat       Date:  2021-07-21       Impact factor: 2.570

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.